Autolus Therapeutics plc - American Depositary Share (AUTL): Price and Financial Metrics


Autolus Therapeutics plc - American Depositary Share (AUTL)

Today's Latest Price: $5.44 USD

0.18 (-3.20%)

Updated Mar 27 12:00am

Add AUTL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 337 in Biotech

See all "A" rated Strong Buy stocks

AUTL Stock Summary

  • Autolus Therapeutics plc's stock had its IPO on June 22, 2018, making it an older stock than just 3.06% of US equities in our set.
  • For AUTL, its debt to operating expenses ratio is greater than that reported by only 0.34% of US equities we're observing.
  • With a price/sales ratio of 69.3, Autolus Therapeutics plc has a higher such ratio than 98.09% of stocks in our set.
  • Stocks that are quantitatively similar to AUTL, based on their financial statements, market capitalization, and price volatility, are ARVN, BLUE, CLLS, TBPH, and ASMB.
  • AUTL's SEC filings can be seen here. And to visit Autolus Therapeutics plc's official web site, go to www.autolus.com.
AUTL Daily Price Range
AUTL 52-Week Price Range

AUTL Stock Price Chart More Charts


AUTL Price/Volume Stats

Current price $5.44 52-week high $32.84
Prev. close $5.62 52-week low $3.00
Day low $4.57 Volume 81,600
Day high $5.73 Avg. volume 194,785
50-day MA $8.66 Dividend yield N/A
200-day MA $12.19 Market Cap 218.39M

Autolus Therapeutics plc - American Depositary Share (AUTL) Company Bio


Autolus Therapeutics is developing a pipeline of advanced programmable T cell treatment candidates for blood and solid tumor cancers. Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I), or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma. The company is based in London, England.


AUTL Latest News Stream


Event/TimeNews Detail
Loading, please wait...

AUTL Latest Social Stream


Loading social stream, please wait...

View Full AUTL Social Stream

AUTL Price Returns

1-mo -33.50%
3-mo -61.39%
6-mo -53.82%
1-year -82.71%
3-year N/A
5-year N/A
YTD -58.79%
2019 -59.81%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6907 seconds.